Roche Diagnostics has received FDA clearance for the 9-minute STAT Parathyroid Hormone test on the Elecsys® 1010 and 2010 systems and cobas e 411 analyzer.

Delivers rapid turnaround while retaining excellent sensitivity and precision

Roche Diagnostics today announced that it has received FDA clearance for the 9-minute STAT Parathyroid Hormone (PTH) test on the Elecsys^® 1010 and 2010 systems and cobas e 411 analyzer. Roche is the only diagnostics company to offer a 9-minute STAT PTH test on an automated immunoassay platform.

PTH is an immunoassay for the in-vitro quantitative determination of intact parathyroid hormone in human serum and plasma for the differential diagnosis of hypercalcemia and hypocalcemia.

Electrochemiluminescence (ECL) technology delivers excellent analytical sensitivity and specificity on PTH tests for the Elecsys 1010 and 2010 systems and cobas e 411 analyzer. The combination of speed and precision can provide improved healthcare outcomes for both the physician and the patient.

The STAT PTH test offers excellent precision, lower detection limit and measuring range and the rapid turnaround time physician’s demand.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, a market leader in virology and active in other major therapeutic areas such as autoimmune diseases, inflammation, metabolism and central nervous system. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 worldwide and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. Additional information about Roche Diagnostics can be found at www.roche-diagnostics.us. 

All trademarks used or mentioned in this release are protected by law.

For further information please contact: